Calithera Biosciences (CALA) Reaches $10.65 After 3.00% Down Move; Berkshire Hills Bancorp (BHLB) Has 1.43 Sentiment

November 14, 2017 - By Migdalia James

The stock of Calithera Biosciences Inc (NASDAQ:CALA) is a huge mover today! About 703,313 shares traded or 26.81% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since November 14, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.The move comes after 8 months negative chart setup for the $377.83 million company. It was reported on Nov, 14 by Barchart.com. We have $10.33 PT which if reached, will make NASDAQ:CALA worth $11.33 million less.

Berkshire Hills Bancorp, Inc. is a holding firm for Berkshire Bank (the Bank) and Berkshire Insurance Group. The company has market cap of $1.65 billion. Berkshire offers a range of deposit, lending, insurance and wealth management products to retail, commercial, not-for-profit and municipal clients in its market areas. It has a 19.69 P/E ratio. Berkshire product offerings also include retail and commercial electronic banking, commercial cash management and commercial interest rate swaps.




Analysts await Calithera Biosciences Inc (NASDAQ:CALA) to report earnings on March, 15. They expect $-0.24 earnings per share, up 46.67% or $0.21 from last year’s $-0.45 per share. After $-0.17 actual earnings per share reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts 41.18% negative EPS growth.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. H.C. Wainwright maintained Calithera Biosciences Inc (NASDAQ:CALA) rating on Monday, June 12. H.C. Wainwright has “Buy” rating and $1900 target. The stock has “Buy” rating by H.C. Wainwright on Tuesday, March 28. Citigroup upgraded the shares of CALA in report on Tuesday, January 24 to “Neutral” rating. JMP Securities maintained Calithera Biosciences Inc (NASDAQ:CALA) on Wednesday, March 9 with “Market Outperform” rating. Citigroup initiated the stock with “Sell” rating in Tuesday, October 25 report. Citigroup initiated Calithera Biosciences Inc (NASDAQ:CALA) on Friday, July 24 with “Buy” rating. The stock of Calithera Biosciences Inc (NASDAQ:CALA) has “Buy” rating given on Thursday, January 5 by H.C. Wainwright.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $377.83 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Investors sentiment decreased to 3.25 in Q2 2017. Its down 2.64, from 5.89 in 2017Q1. It turned negative, as 11 investors sold Calithera Biosciences Inc shares while 9 reduced holdings. 34 funds opened positions while 31 raised stakes. 49.95 million shares or 37.35% more from 36.36 million shares in 2017Q1 were reported. Nationwide Fund owns 44,731 shares. Pnc Financial Ser Grp has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Atika Cap Mgmt Limited Liability has invested 1.35% in Calithera Biosciences Inc (NASDAQ:CALA). Jacobs Levy Equity Mgmt holds 18,565 shares. Howland Mgmt Ltd Limited Liability Company invested 0.02% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Howard Hughes Medical Institute has invested 0.01% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Bnp Paribas Arbitrage Sa has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 3,209 shares. Royal Comml Bank Of Canada has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 133 shares. Vanguard Group Inc owns 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 1.20 million shares. Pacad Invest Ltd has 33,416 shares. Moreover, Aqr Cap Mngmt Limited Liability Com has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 35,161 shares. Weiss Multi stated it has 10,000 shares or 0.01% of all its holdings. Geode Capital Mngmt Ltd Limited Liability Company owns 233,958 shares. Fmr Limited Liability Corporation holds 0.01% or 2.72M shares in its portfolio. Wells Fargo & Com Mn reported 26,832 shares stake.

Jacobs Asset Management Llc holds 5.87% of its portfolio in Berkshire Hills Bancorp, Inc. for 826,034 shares. Godshalk Welsh Capital Management Inc. owns 36,000 shares or 1.26% of their US portfolio. Moreover, Maltese Capital Management Llc has 1.16% invested in the company for 347,827 shares. The Illinois-based Perritt Capital Management Inc has invested 1.03% in the stock. Eagle Boston Investment Management Inc, a Massachusetts-based fund reported 264,074 shares.

About 35,263 shares traded. Berkshire Hills Bancorp, Inc. (BHLB) has risen 33.85% since November 14, 2016 and is uptrending. It has outperformed by 17.15% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.